Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imetelstat + azacitidine + venetoclax
- Development stage
- Phase 1
- Lead developer
- Geron
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Rytelo + azacitidine + venetoclax is an investigational three-drug combination regimen being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (AML). The combination consists of imetelstat (Rytelo), a telomerase-inhibiting oligonucleotide developed by Geron; azacitidine (Vidaza), a hypomethylating nucleoside analog; and venetoclax (Venclexta), an oral selective BCL-2 inhibitor. This regimen is being evaluated in the Phase 1 IMAGINE trial (NCT07320235) to determine safety, tolerability, and preliminary efficacy, specifically focusing on finding the optimal biological dose of imetelstat in combination with azacitidine and venetoclax. Preclinical studies have demonstrated that the combination of imetelstat and venetoclax exhibits synergistic pro-apoptotic activity in AML cell lines and patient-derived samples.
- Other names
- Rytelo + Vidaza + VenclextaRytelo + azacitidine + venetoclax
02
Targets
BCL-2 (BCL-2 family)DNMT1 (DNA (cytosine-5)-methyltransferase 1)TERT (Telomerase)
Beyond the preview
Go deeper on imetelstat + azacitidine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imetelstat + azacitidine + venetoclax.